4D Pharma plc, of Leeds, U.K., said data published in PLOS One showed that specific single bacterial strains from the human gut microbiota have the potential to serve as therapeutic inhibitors of HDAC, which is particularly relevant for disease areas involving host epigenetic aberrations.